Prolia and Xgeva QT Interval Heart Injury

Drug Liability Attorneys in New York City

Prolia and Xgeva (active ingredient denosumab), a drug manufactured by Amgen, is used to combat osteoporosis. Women receive injections every six months. Denosumab is known to cause a sudden decrease in a patient's calcium level (hypocalcaemia) and doctors are expected to use it with great care in patients with a preexisting calcium deficiency. Recent reports now link the hypocalcaemia to conditions which may lead to sudden death.

At Rheingold Giuffra Ruffo & Plotkin LLP, lead attorney Paul Rheingold led out firm's successful litigation against Janssen and Johnson & Johnson for the Propulsid QT Interval litigation after the drug was removed from the market in 2000. If you or someone you know has suffered from Prolia or Xgeva, our team has the experience and resources to help.

Contact us today online or by telephone at (888) 260-0473 to speak with a knowledgeable New York defective drug lawyer. Our firm handles a case from start to finish.

Adverse Effects from Hypocalcemia

In August 2016, new warnings were added to Prolia and Xgeva by the Australian Government Therapeutic Goods Administration. Side effect reports showed that serum calcium levels became so low that the following side effects occurred:

  • QT interval prolongation leading to cardiac arrest and sudden death
  • Tetany
  • Seizures
  • Altered mental status

What is a QT Interval Prolongation?

In cardiology, the QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QT interval represents electrical depolarization and repolarization of the ventricles. Calcium ions pass back and forth across cell membrane and generate the electrical activity (depolarization and repolarization) that initiates the heart's mechanical function. A rapid depletion of calcium from the use of Prolia and Xgeva can lead to serious side effects. That is why the Australian Government Therapeutic Goods Administration has demanded stronger warnings.

Client Focused Litigation

This is not a class action where you are piled in with other victims and given a token settlement or coupon! Your case is personal to you. All decisions are made with you and only you. Many drug product liability cases evolve into two choices: participate in a settlement plan or litigating to a trial. The choice is yours and no one forces you into one option or another. Settlement plans often provide significant recoveries without the delays and expenses associated with trials.

Whether the litigation has settlements or trials, the drug companies will be forced to answer for what has been done. In drug product litigation, pharmaceutical companies are forced to turn over millions of internal documents which reveal what happened and why. This work sometimes gets the Department of Justice to levy fines. In certain very egregious cases, the FBI has even sought to investigate criminal issues. A wave of litigation and trial verdicts forces corporate boards to "face the music" with shareholders and Wall Street.

Have you or someone close to you been harmed by Prolia or Invega? Please contact us at (888) 260-0473 to speak to an experienced New York dangerous drugs liability attorney. Our law office is conveniently located in a brownstone in Midtown Manhattan located at 113 East 37th Street.

Results Feed Header

Prev Next

Don't Settle

for an Average Attorney
    • Please enter your name.
    • This isn't a valid phone number.
    • Please enter your email address.
      This isn't a valid email address.
    • Please make a selection.
    • Please enter a message.
Get RGRP On Your Side